touchONCOLOGY joins Prof Lyudmila A Bazhenova (University of California San Diego, CA) at WCLC 2021 to discuss the challenges faced when expanding patients receiving immunotherapy for the treatment of non-small cell lung cancer.
Questions
1. What has been the impact of immunotherapy in the treatment of non-small cell lung cancer (NSCLC)? (00:12-00:51)
2. What are the current challenges to the widespread use of immunotherapy? (00:51-02:19)
3. What factors affect the decision to prescribe immunotherapy to a patient with NSCLC? (02:19-02:56)
4. What are the challenges to expanding who gets immunotherapy and how can these be overcome? (02:56-04:09)
5. What further research is needed? (04:09-05:09)
Disclosures: Lyudmila Bazhenova has been an advisory board member for Merck, Daichi Sankyo, Turning Point, Janssen, Novartis, Neuvogen, BMS and Boehringer Ingelheim. She also discloses stock for Epic Sciences.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 WCLC Annual Meeting.
